Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport : Methodology, Pitfalls, and Interpretation

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/302836

Lähdeviite

Tornio , A , Filppula , A M , Niemi , M & Backman , J T 2019 , ' Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport : Methodology, Pitfalls, and Interpretation ' , Clinical Pharmacology and Therapeutics , vol. 105 , no. 6 , pp. 1345-1361 . https://doi.org/10.1002/cpt.1435

Julkaisun nimi: Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport : Methodology, Pitfalls, and Interpretation
Tekijä: Tornio, Aleksi; Filppula, Anne M.; Niemi, Mikko; Backman, Janne T.
Tekijän organisaatio: Department of Clinical Pharmacology
INDIVIDRUG - Individualized Drug Therapy
Research Programs Unit
Medicum
Clinicum
Mikko Olavi Niemi / Principal Investigator
Janne Backman / Principal Investigator
HUSLAB
Päiväys: 2019-06
Kieli: eng
Sivumäärä: 17
Kuuluu julkaisusarjaan: Clinical Pharmacology and Therapeutics
ISSN: 0009-9236
DOI-tunniste: https://doi.org/10.1002/cpt.1435
URI: http://hdl.handle.net/10138/302836
Tiivistelmä: Many drug-drug interactions (DDIs) are based on alterations of the plasma concentrations of a victim drug due to another drug causing inhibition and/or induction of the metabolism or transporter-mediated disposition of the victim drug. In the worst case, such interactions cause more than tenfold increases or decreases in victim drug exposure, with potentially life-threatening consequences. There has been tremendous progress in the predictability and modeling of DDIs. Accordingly, the combination of modeling approaches and clinical studies is the current mainstay in evaluation of the pharmacokinetic DDI risks of drugs. In this paper, we focus on the methodology of clinical studies on DDIs involving drug metabolism or transport. We specifically present considerations related to general DDI study designs, recommended enzyme and transporter index substrates and inhibitors, pharmacogenetic perspectives, index drug cocktails, endogenous substrates, limited sampling strategies, physiologically-based pharmacokinetic modeling, complex DDIs, methodological pitfalls, and interpretation of DDI information.
Avainsanat: TIME-DEPENDENT PHARMACOKINETICS
PLASMA-CONCENTRATIONS
ROSUVASTATIN PHARMACOKINETICS
INTERACTION ASSESSMENTS
ENDOGENOUS BIOMARKERS
MARKEDLY DECREASES
GRAPEFRUIT JUICE
GENEVA COCKTAIL
CYTOCHROME-P450
INHIBITION
317 Pharmacy
3111 Biomedicine
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by_nc_nd
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: acceptedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
Clinical_Studies_on_Drug_Drug_Interactions.pdf 775.3KB PDF Avaa tiedosto
Clinical_Studie ... lls_and_Interpretation.pdf 732.0KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot